Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of add-on therapy of sitagliptin in Japanese patients with type 2 diabetes under insulin therapy

  • Original Article
  • Published:
Diabetology International Aims and scope Submit manuscript

An Erratum to this article was published on 28 February 2014

Abstract

Objective

To examine the impact of add-on sitagliptin therapy on glucose, endogenous insulin and glucagon concentrations in Japanese patients with type 2 diabetes under insulin therapy.

Research design and methods

Sixty-two patients (mean age 59.0 years) undergoing insulin therapy were treated with add-on sitagliptin, and various parameters including HbA1c were compared before and 4 months after sitagliptin administration by the paired t-test. Multivariate analysis was performed to further identify factors independently associated with some outcomes of the therapy, including the reduction of HbA1c and the desirable outcome (reduction of HbA1c without increase in BW).

Results

There were significant decreases in mean HbA1c (8.6–7.7 %), mean PG at 60 min and 120 min in the meal tolerance test (MTT) (242–212 and 228–196 mg/dL) (p < 0.005), significant increases in mean C-peptide reactivity (CPR) at 0 and 60 min in the MTT (1.00–1.14 and 1.63–1.78 ng/mL) (p < 0.05), and significant decreases in mean glucagon at 60 and 120 min in the MTT (88.2–81.5 and 85.4–78.8 pg/mL) (p < 0.05). There was neither a significant change in mean BW nor serious adverse events including episodes of severe hypoglycemia. Multivariate regression analysis showed that baseline HbA1c was the only factor related to the change in HbA1c by sitagliptin add-on therapy. Multiple logistic regression analysis revealed that a bolus insulin dose of ≥15 units/day was significantly associated with the desirable outcome.

Conclusions

Add-on sitagliptin therapy may be a new therapeutic option in patients with type 2 diabetes who have inadequate glycemic control with insulin therapy, possibly using a bolus insulin dose of ≥15 units/day.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40.

    Article  CAS  PubMed  Google Scholar 

  2. Kobayashi M, Yamazaki K, Hirao K, Oishi M, Kanatsuka A, Yamauchi M, Takagi H, Kawai K, Japan Diabetes Clinical Data Management Study Group. The status of diabetes control and antidiabetic drug therapy in Japan—a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract. 2006;73:198–204.

    Article  PubMed  Google Scholar 

  3. Wright AD, Cull CA, Macleod KM, Holman RR, UKPDS Group. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complicat. 2006;20:395–401.

    Article  PubMed  Google Scholar 

  4. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.

    Article  CAS  PubMed  Google Scholar 

  5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.

    Article  Google Scholar 

  6. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G, ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–43.

    Article  CAS  PubMed  Google Scholar 

  7. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010;1:8–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:262–9.

    Article  CAS  PubMed  Google Scholar 

  9. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1, 2, 4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:141–51.

    Article  CAS  PubMed  Google Scholar 

  10. Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab. 2010;12:613–22.

    Article  CAS  PubMed  Google Scholar 

  11. Odawara M, Kadowaki T, Tajima N, Nishii M, Taniguchi T, Arjona Ferreira JC. Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetol Int. 2011;2:94–105.

    Article  Google Scholar 

  12. Tajima N, Kadowaki T, Odawara M, Nishii M, Taniguchi T, Arjona Ferreira JC. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetol Int. 2011;2:32–44.

    Article  Google Scholar 

  13. Kubota A, Matsuba I, Saito T, Nabe K, Seino Y. Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus. J Diabetes Investig. 2011;2:377–80.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I, ASSET-K Study group. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract. 2012;95:e20–2.

    Article  CAS  PubMed  Google Scholar 

  15. Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, Minagawa F, Obana M, Iemitsu K, Ito S, Amamiya H, Kaneshiro M, Takai M, Kaneshige H, Hoshino K, Ishikawa M, Minami N, Takuma T, Sasai N, Aoyagi S, Kawata T, Mokubo A, Takeda H, Honda S, Machimura H, Motomiya T, Waseda M, Nakal Y, Tanaka Y, Terauchi Y, Matsuba I. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Investig. 2012;3:503–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, Minagawa F, Obana M, Iemitsu K, Ito S, Amemiya H, Kaneshiro M, Takai M, Kaneshige H, Hoshino K, Ishikawa M, Minami N, Takuma T, Sasai N, Aoyagi S, Kawata T, Mokubo A, Takeda H, Honda S, Machimura H, Motomiya T, Waseda M, Naka Y, Tanaka Y, Terauchi Y, Matsuba I. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res. 2012;4:309–13.

    CAS  PubMed Central  PubMed  Google Scholar 

  17. Vilsbøll T, Rosenstock J, Yki-Järvinen H, Cefalu WT, Chen Y, Luo E, Musser B, Andryuk PJ, Ling Y, Kaufman KD, Amatruda JM, Engel SS, Katz L. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:167–77.

    Article  PubMed  Google Scholar 

  18. Kadowaki T, Tajima N, Odawara M, Minamide T, Kawashima M, Yanagida D, Taniguchi T, ArjonaFerreira JC. Addition of sitagliptin, an oral, highly-selective dipeptidyl peptidase-4 inhibitor, improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetes. 2011;Supple 1:A279.

    Google Scholar 

  19. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H, Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig. 2012;3:39–40.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Hong ES, Khang AR, Yoon JW, Kang SM, Choi SH, Park KS, Jang HC, Shin H, Walford GA, Lim S. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab. 2012;14:795–802.

    Article  CAS  PubMed  Google Scholar 

  21. Katsuno T, Ikeda H, Ida K, Miyagawa JI, Namba M. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocr J. 2013;60:733–42

    Article  CAS  PubMed  Google Scholar 

  22. Mori Y, Taniguchi Y, Miyazaki S, Yokoyama J, Utsunomiya K. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy. Diabetes Technol Ther. 2013;15:237–40.

    Article  CAS  PubMed  Google Scholar 

  23. Nagai E, Katsuno T, Miyagawa J, Konishi K, Miuchi M, Ochi F, Kusunoki Y, Tokuda M, Murai K, Hamaguchi T, Namba M. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus. Endcr J. 2011;58:869–77.

    Article  CAS  Google Scholar 

  24. Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, Terauchi Y. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta Diabetol. 2012;49:225–30.

    Article  PubMed  Google Scholar 

  25. Ohlsson L, Alsalim W, Carr RD, Tura A, Pacini G, Mari A, Ahren B. Glucose lowering effect of the DPP4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. Diabetes Obes Metab. 2013;13:531–7.

    Article  Google Scholar 

  26. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013. doi:10.2337/db12-1686.

    Google Scholar 

  27. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696–708.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. Naoyuki Kamatani, M.D., Ph.D., a specialist in medical statistics in StaGen Co. Ltd. for his advice concerning statistical analyses used in the present manuscript. All of the authors declare no conflict of interest associated with this manuscript.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Diabetes Center, Tokyo Women’s Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

    Tomoko Nakagami, Risa Ide, Naoko Iwasaki, Makiko Ogata, Junko Oya, Nobue Tanaka, Hiroko Takaike, Asako Sato, Junnosuke Miura & Yasuko Uchigata

  2. Institute of Geriatrics, Tokyo Women’s Medical University, Tokyo, Japan

    Mari Osawa

  3. Laboratory Medicine, Tokyo Women’s Medical University, Tokyo, Japan

    Asako Sato

Authors
  1. Tomoko Nakagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Risa Ide
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoko Iwasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Makiko Ogata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Junko Oya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mari Osawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nobue Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroko Takaike
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Asako Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Junnosuke Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yasuko Uchigata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomoko Nakagami.

About this article

Cite this article

Nakagami, T., Ide, R., Iwasaki, N. et al. Evaluation of add-on therapy of sitagliptin in Japanese patients with type 2 diabetes under insulin therapy. Diabetol Int 5, 187–197 (2014). https://doi.org/10.1007/s13340-013-0155-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-013-0155-6

Keywords

Search

Navigation